Do we know enough? What questions should you be asking?
Over the past two years, GLP-1 medications have transformed the conversation around weight.
Originally developed for managing type 2 diabetes , drugs such as semaglutide (commonly known by brand names including Ozempic and Wegovy) are now widely prescribed for weight loss.
For many individuals, the results can appear dramatic. Weight reductions of 10–15% of body mass are common in clinical trials. But as these medications become more widely used, an important question is beginning to emerge:
What happens after the weight loss?
Understanding GLP-1 Medications
GLP-1 drugs work by mimicking a hormone called glucagon-like peptide-1, which plays a role in appetite regulation and blood sugar balance. These medications:
• slow gastric emptying (the process of your stomach moving food into your small intestine after you eat)
• increases feelings of fullness
• reduce appetite signals in the brain
• improve insulin sensitivity
As a result, people often consume significantly fewer calories.
While this can produce rapid weight loss, it also introduces new physiological considerations.
Emerging Challenges
As GLP-1 use has expanded, doctors are beginning to observe new patterns.
Commonly reported side effects include:
• nausea and gastrointestinal distress
• dehydration
• reduced appetite leading to inadequate calorie intake
• nutrient deficiencies
• muscle loss
• hair thinning
In some cases, more serious complications have also been reported, including rare but concerning events such as vision complications linked to optic nerve damage. (GLP-1 medications (like Ozempic) are thought to potentially increase the risk of optic nerve damage by altering blood pressure, blood flow, and metabolic balance in ways that may reduce circulation to the eye in vulnerable individuals.)
While these outcomes remain uncommon, they highlight the importance of understanding that rapid weight loss interventions can have complex systemic effects.
The Transition Question
Another issue many patients encounter is what happens when the medication stops. Many people use GLP-1’s for 6–12 months for initial weight loss, while some continue for 1–2+ years to maintain results.
Clinical studies show that a significant proportion of individuals regain weight after discontinuing GLP-1 medications. This is largely because:
• appetite hormones return to baseline
• metabolic rate may have slowed
• underlying lifestyle patterns remain unchanged
Without long-term nutritional support and metabolic stability, the body often returns to its previous equilibrium.
Supporting the Body During and After GLP-1
For individuals who choose to use GLP-1 medications under medical supervision, it becomes essential to support the body during this period.
Key considerations include:
• maintaining adequate protein intake
• supporting gut health
• ensuring sufficient micronutrients
• protecting lean muscle mass
• maintaining hydration and electrolytes
This is where nutritional foundations become particularly important.
Nourishment as the Next Step
Products such as The Super Elixir™ can help support nutrient intake and digestive health during periods when appetite may be reduced. Our Nourishing Protein provides plant-based amino acids that support muscle maintenance and satiety.
These tools can help ensure the body receives the nutrients it needs even when calorie intake fluctuates.
The Bigger Picture
GLP-1 medications may offer meaningful support for certain individuals when prescribed appropriately. But they are not a complete wellness strategy. True metabolic resilience still depends on:
• balanced nutrition
• gut health
• muscle strength
• stress regulation
• sleep quality
These foundations remain essential long after any medication protocol ends.
Sustainable Wellness
Our philosophy has always centred on supporting the body’s natural systems first.
Because while rapid interventions may shift the scale quickly, true wellness is built slowly.
Through nourishment. Through consistency. Through daily routines that support the body’s long-term health.